Competition of Agencies in European Pharmaceutical Law - Does It Exist, Is It Desirable and How to Handle It?
License
Access Rights
Cadmus Permanent Link
Full-text via DOI
ISBN
ISSN
2190-8249 (electronic); 1867-299X (print)
Issue Date
Type of Publication
Keyword(s)
LC Subject Heading
Other Topic(s)
EUI Research Cluster(s)
Initial version
Published version
Succeeding version
Preceding version
Published version part
Earlier different version
Initial format
Author(s)
Citation
European journal of risk regulation (EJRR), 2010, 3, 227-238
Cite
PURNHAGEN, Kai Peter, Competition of Agencies in European Pharmaceutical Law - Does It Exist, Is It Desirable and How to Handle It?, European journal of risk regulation (EJRR), 2010, 3, 227-238 - https://hdl.handle.net/1814/14917
Abstract
Rarely has international law been investigated from a Business to Agency (B2A) or even Agency to Agency (A2A) perspective. In recent years, the 'mushrooming' of agencies at European level has triggered the importance of looking more closely into the relationship of the agencies towards each other. Is there a struggle over competences and regulatory objects, and would such competition lead to desirable outcomes? In this paper I will first show that, due to the historical development of administrative law in Europe and the USA, the perception of the desirability of agency competition differs. I will then contrast these findings with EU pharmaceutical law and show that it tends to avoid competition. Also, in practice, competition among agencies is still exceptional for European pharmaceutical regulation. Finally, I conclude these findings and hint at the limits of the desired process for further coherence. Although a move towards even greater convergence in European risk regulation is desirable, it does have its limits set by the principle of conferral in Article 5 (1, 2) EU read in conjunction with the areas of shared competence and the competence to support, coordinate and supplement.